# Ajax Therapeutics

**Canonical:** https://apis.io/providers/ajak-therapeutics/  
**Website:** https://www.lilly.com/science/subsidiaries  
**APIs profiled:** 1

Ajax Therapeutics is a biotechnology company focused on developing novel therapies for myelofibrosis and polycythemia vera. In 2026, Eli Lilly announced the acquisition of Ajax Therapeutics to advance outcomes for patients with these serious blood disorders, integrating Ajax’s pipeline into Lilly’s broader research portfolio.

## Kin Score — 3.9 / 100 (minimal)

Scored 2026-09-25 under rubric 0.23.0. Trend: flat (-1.7 from 5.6).

| Facet | Score |
|---|---|
| Discoverability | 53.6 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 5.9 (matched via fallback).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## APIs (1)

- **Ajax Therapeutics API** — Ajax Therapeutics does not expose a public API; no documentation host or machine‑readable specification was found.

## Security (1)

- **Ajak Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Therapeutics, Myelofibrosis, Polycythemia Vera

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/ajak-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.